Latest News for: her3

Edit

Her3-Targeted Immunotherapies Pipeline and Competitive Intelligence Report

Nasdaq Globe Newswire 27 Nov 2025
Her3-targeted immunotherapies present key opportunities in oncology due to widespread HER3 overexpression in various cancers, ...
Edit

Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, ...

Business Wire 10 Nov 2025
SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate ... .
Edit

SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025

PR Newswire 17 Oct 2025
Iza-bren's dual mechanism of action blocks EGFR and/or HER3 signals to cancer cells, reducing cancer cell proliferation and survival.
Edit

The Department of Clinical and Molecular Medicine of Sapienza University of Rome, Takis and Tethis start a collaboration to advance HER3-targeted therapies and diagnostics

PR Newswire 03 Oct 2025
today announce a joint initiative, to accelerate research on HER3-targeted therapies and advance the development of companion diagnostics for lung cancer patients ... which binds the HER3 receptor.
Edit

Debiopharm Licenses SunRock Biopharma’s Anti-HER3/HER2 Antibody to Explore the Full Potential of Bispecific ADC Debio 2512

The Galveston Daily News 30 Sep 2025
LAUSANNE, Switzerland & SANTIAGO DE COMPOSTELA, Spain--(BUSINESS WIRE)--Sep 30, 2025-- ....
  • 1

Article Search

tools
×
×
×
×